Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

36.50 USD -0.23 (-0.63%)
Official Closing Price Updated: 5:37 PM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
From GlobeNewswire News Releases
Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?
InvestorsObserver issues critical PriceWatch Alerts for AAXN, TLRY, PFE, CRSP, and GM. 
From PR Newswire
Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric... 
From Business Wire News Releases
Thinking about trading options or stock in Plug Power, Pfizer, Carnival Corp, American Airlines, or Bilibili?
InvestorsObserver issues critical PriceWatch Alerts for PLUG, PFE, CCL, AAL, and BILI. 
From PR Newswire
Researchers Seek to Better Understand Psychedelics' Role in New Therapies
FinancialBuzz.com News Commentary 
From PR Newswire
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative. 
From Business Wire News Releases
PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
PureTech Founded Entity Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative. 
From Business Wire News Releases
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth... 
From Business Wire News Releases
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines 
From Business Wire News Releases
CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophy
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) announcement surrounding the first dosing of... 
From Business Wire News Releases
Thinking about trading options or stock in Nio, Plug Power, Pfizer, Sorrento Therapeutics, or BioNTech?
InvestorsObserver issues critical PriceWatch Alerts for NIO, PLUG, PFE, SRNE, and BNTX. 
From PR Newswire
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
From GlobeNewswire News Releases
Thinking about trading options or stock in Pfizer, Tesla, General Motors, JPMorgan Chase, or UnitedHealth Group?
InvestorsObserver issues critical PriceWatch Alerts for PFE, TSLA, GM, JPM, and UNH. 
From PR Newswire
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
Corinne Le Goff, Pharm.D. will join Moderna as Chief Commercial Officer on January 19. 
From Business Wire News Releases
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate... 
From Business Wire News Releases
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8... 
From PR Newswire
Thinking about buying stock in Citigroup, Pfizer, CleanSpark, FuelCell Energy, or BP?
InvestorsObserver issues critical PriceWatch Alerts for C, PFE, CLSK, FCEL, and BP. 
From PR Newswire
Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy
Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of... 
From PR Newswire
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39th Annual J.P. Morgan Healthcare Conference to be held... 
From Business Wire News Releases
Thinking about trading options or stock in Pfizer, Tesla, Goldman Sachs, Caterpillar, or Walmart?
InvestorsObserver issues critical PriceWatch Alerts for PFE, TSLA, GS, CAT, and WMT. 
From PR Newswire
Thinking about trading options or stock in Nio, Pfizer, CleanSpark, Roku, or Apple?
InvestorsObserver issues critical PriceWatch Alerts for NIO, PFE, CLSK, ROKU, and AAPL. 
From PR Newswire
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for... 
From Business Wire News Releases
Thinking about buying stock in AstraZeneca, Pfizer, JD.Com, General Electric, or Boeing?
InvestorsObserver issues critical PriceWatch Alerts for AZN, PFE, JD, GE, and BA. 
From PR Newswire
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU)... 
From Business Wire News Releases
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
From GlobeNewswire News Releases
Thinking about trading options or stock in Apple, Pfizer, Alibaba, Snap, or Moderna?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, PFE, BABA, SNAP, and MRNA. 
From PR Newswire
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a... 
From Business Wire News Releases
UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
From GlobeNewswire News Releases
Thinking about trading options or stock in Pfizer, General Electric, Apple, Blink Charging, or AstraZeneca?
InvestorsObserver issues critical PriceWatch Alerts for PFE, GE, AAPL, BLNK, and AZN. 
From PR Newswire
Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.